drugset / Trial / NCT06500598

Compassionate Use of Evinacumab

NCT06500598 ↗

Expanded access Approved for marketing Regeneron Pharmaceuticals

Summary

Provide compassionate use of evinacumab

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Evinacumab Monoclonal antibody — —